SAN DIEGO, CA--(Marketwired - Oct 1, 2013) - NuVasive, Inc. (
NuVasive will exhibit and demonstrate the Company's game-changing products and procedures, including XLIF®, Precept®, Armada®, MAS® PLIF, and the NVM5® neuromonitoring system.
"We are very excited to exhibit our procedurally integrated solutions at EuroSpine 2013," said Russell Powers, NuVasive Executive Vice President of International. "As we continue to build our international footprint, EuroSpine provides an excellent forum to demonstrate the value of our products and procedures and allows NuVasive a great opportunity to interact and build upon relationships with surgeons from throughout the world."
The annual EuroSpine conference is an important event for orthopedic, trauma, and neurosurgeons to come together to share the latest findings from their research.
"EuroSpine is one of the most widely attended conferences for international spine research, with more than 3,000 spine experts, renowned surgeons, and healthcare and industry professionals expected to attend," said Paul Kosters, NuVasive Senior Vice President of Europe, Middle East, and Africa. "The meeting will be instrumental to our growth in Europe, enabling us to showcase our latest advances in minimally disruptive products and procedures and interact with the talented surgeons and healthcare professionals in Europe."
NuVasive is scheduled to participate in the following events at EuroSpine:
- NuVasive Technical Exhibit Booth #A27: The NuVasive technical exhibit booth will feature a number of innovative, minimally disruptive products and procedures, including: XLIF®, Precept®, Armada®, MAS® PLIF, and our NVM5® neuromonitoring system.
- NuVasive Lunch Workshop: NuVasive, along with surgeon proctors Dr. Pedro Berjano, Italy; Mr. Alwyn Jones, United Kingdom; and Professor Claudio Lamartina, Germany; will host a hands-on workshop on Wednesday, October 2, 2013 from 12:00 p.m. to 2:00 p.m. GMT in room 14. The workshop is titled "Advanced Applications of eXtreme Lateral Interbody Fusion (XLIF) and Percutaneous Fixation."
For more information about EuroSpine 2013, please visit: http://www.eurospine2013.eu/
EuroSpine, the Spine Society of Europe, was founded in June 26, 1998, in Innsbruck, Austria. The purpose of EuroSpine is to provide a platform in European countries for the exchange of knowledge and ideas in the field of research, prevention, and treatment of spine diseases.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons worldwide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.